Wedmont Private Capital Raises Stake in IQVIA Holdings Inc. (NYSE:IQV)

Wedmont Private Capital boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 9.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,042 shares of the medical research company’s stock after buying an additional 178 shares during the quarter. Wedmont Private Capital’s holdings in IQVIA were worth $460,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Canada Pension Plan Investment Board lifted its position in IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares during the last quarter. Lazard Asset Management LLC raised its holdings in IQVIA by 0.9% in the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after purchasing an additional 30,014 shares in the last quarter. Farallon Capital Management LLC raised its holdings in IQVIA by 3.1% in the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after purchasing an additional 86,870 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in IQVIA by 3.8% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock worth $634,927,000 after purchasing an additional 92,293 shares in the last quarter. Finally, Capital Research Global Investors grew its stake in shares of IQVIA by 7.2% in the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after acquiring an additional 143,533 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $229.24 on Friday. The stock has a market capitalization of $41.79 billion, a PE ratio of 29.77, a P/E/G ratio of 2.18 and a beta of 1.49. The business has a 50 day simple moving average of $239.41 and a two-hundred day simple moving average of $231.99. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73.

IQVIA (NYSE:IQV) last announced its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The firm had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.22 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on IQV shares. JPMorgan Chase & Co. increased their target price on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. UBS Group increased their price objective on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Evercore ISI dropped their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday. Truist Financial increased their target price on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Finally, StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Five equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $269.36.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.